Phase 3 Readout

GILD: Phase 3 Topline: A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, an

Name: Phase 3 Topline: A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, an
Start: 2027-03-01
End: 2027-03-01

March 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 1, 2027
Company: GILEAD SCIENCES, INC. (GILD)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, an

March 1, 2027

GILD overview →

Company: GILEAD SCIENCES, INC. (GILD)
Indication: HIV Infections; Acquired Immune Deficiency Syndrome (AIDS)